- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | HCH drug potential boosts Tyra Biosciences' stock PT at H.C. Wainwright | 2 | Investing.com | ||
| 20.03. | Tyra Biosciences Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 19.03. | Tyra Biosciences files to sell 15.37M shares of common stock for holders | 1 | Seeking Alpha | ||
| 19.03. | Tyra Biosciences GAAP EPS of -$0.53 misses by $0.05 | 1 | Seeking Alpha | ||
| 19.03. | Tyra Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Tyra Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights | 81 | PR Newswire | - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 -- TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 -- Initiated SURF201 Phase 1 study and dosed... ► Artikel lesen | |
| 02.02. | Tyra Biosciences spikes on $200M private financing | 4 | Seeking Alpha | ||
| 02.02. | Tyra Biosciences secures $200 million in private financing | 1 | Investing.com | ||
| 02.02. | Tyra Biosciences' TYRA-300 gains FDA rare paediatric disease status | 1 | Pharmaceutical Technology | ||
| 02.02. | Tyra Bio up on FDA's rare pediatric disease tag for dwarfism therapy | 1 | Reuters | ||
| 01.02. | Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia | 192 | PR Newswire | CARLSBAD, Calif., Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target... ► Artikel lesen | |
| 01.02. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.12.23 | Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 | 282 | PR Newswire | - Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300-- Received FDA feedback on TYRA-300 Phase... ► Artikel lesen | |
| 22.12.23 | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.11.23 | Tyra Biosciences GAAP EPS of -$0.49 misses by $0.14 | 1 | Seeking Alpha | ||
| 08.11.23 | Tyra Biosciences Inc reports results for the quarter ended in September - Earnings Summary | - | Reuters | ||
| 07.11.23 | Tyra Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11.23 | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -3,11 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,060 | -0,93 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,862 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,710 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,080 | +0,93 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ASSERTIO | 1,010 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,520 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 9,430 | 0,00 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,030 | 0,00 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,195 | 0,00 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,460 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,590 | 0,00 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,920 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 18,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
